JP2006506465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006506465A5 JP2006506465A5 JP2005505532A JP2005505532A JP2006506465A5 JP 2006506465 A5 JP2006506465 A5 JP 2006506465A5 JP 2005505532 A JP2005505532 A JP 2005505532A JP 2005505532 A JP2005505532 A JP 2005505532A JP 2006506465 A5 JP2006506465 A5 JP 2006506465A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- tnfα
- pharmaceutical composition
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 201000010099 disease Diseases 0.000 claims 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 15
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 15
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 14
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 13
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 13
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 12
- 201000004681 Psoriasis Diseases 0.000 claims 12
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 12
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 7
- 208000011231 Crohn disease Diseases 0.000 claims 7
- 208000002193 Pain Diseases 0.000 claims 7
- 208000007502 anemia Diseases 0.000 claims 7
- 230000001684 chronic effect Effects 0.000 claims 7
- 238000006467 substitution reaction Methods 0.000 claims 7
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 6
- 208000009137 Behcet syndrome Diseases 0.000 claims 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 6
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 6
- 208000006673 asthma Diseases 0.000 claims 6
- 206010012601 diabetes mellitus Diseases 0.000 claims 6
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 6
- 208000037803 restenosis Diseases 0.000 claims 6
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 5
- 102000057041 human TNF Human genes 0.000 claims 5
- 235000004279 alanine Nutrition 0.000 claims 4
- 125000003295 alanine group Chemical class N[C@@H](C)C(=O)* 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000003472 neutralizing effect Effects 0.000 claims 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- 208000005141 Otitis Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 208000019258 ear infection Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 206010058461 Orchitis noninfective Diseases 0.000 claims 1
- 208000003076 Osteolysis Diseases 0.000 claims 1
- 206010048984 Pancreatic abscess Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 206010033649 Pancreatitis chronic Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 208000003152 Yellow Fever Diseases 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 208000003167 cholangitis Diseases 0.000 claims 1
- 208000002849 chondrocalcinosis Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 206010063344 microscopic polyangiitis Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000026721 nail disease Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 208000025487 periodic fever syndrome Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 1
- 208000009169 relapsing polychondritis Diseases 0.000 claims 1
- 208000004124 rheumatic heart disease Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39727502P | 2002-07-19 | 2002-07-19 | |
| US41108102P | 2002-09-16 | 2002-09-16 | |
| US41749002P | 2002-10-10 | 2002-10-10 | |
| US45577703P | 2003-03-18 | 2003-03-18 | |
| PCT/US2003/022566 WO2004009776A2 (en) | 2002-07-19 | 2003-07-18 | TREATMENT OF TNFα RELATED DISORDERS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010057713A Division JP2010209070A (ja) | 2002-07-19 | 2010-03-15 | ＴＮＦα関連疾患の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006506465A JP2006506465A (ja) | 2006-02-23 |
| JP2006506465A5 true JP2006506465A5 (cg-RX-API-DMAC7.html) | 2006-09-14 |
Family
ID=30773676
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005505532A Withdrawn JP2006506465A (ja) | 2002-07-19 | 2003-07-18 | ＴＮＦα関連疾患の治療 |
| JP2010057713A Pending JP2010209070A (ja) | 2002-07-19 | 2010-03-15 | ＴＮＦα関連疾患の治療 |
| JP2012225755A Withdrawn JP2013056892A (ja) | 2002-07-19 | 2012-10-11 | ＴＮＦα関連疾患の治療 |
| JP2015116695A Pending JP2015221798A (ja) | 2002-07-19 | 2015-06-09 | ＴＮＦα関連疾患の治療 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010057713A Pending JP2010209070A (ja) | 2002-07-19 | 2010-03-15 | ＴＮＦα関連疾患の治療 |
| JP2012225755A Withdrawn JP2013056892A (ja) | 2002-07-19 | 2012-10-11 | ＴＮＦα関連疾患の治療 |
| JP2015116695A Pending JP2015221798A (ja) | 2002-07-19 | 2015-06-09 | ＴＮＦα関連疾患の治療 |
Country Status (22)
| Country | Link |
|---|---|
| US (16) | US20040136991A1 (cg-RX-API-DMAC7.html) |
| EP (6) | EP1944322B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP2006506465A (cg-RX-API-DMAC7.html) |
| KR (6) | KR20140058649A (cg-RX-API-DMAC7.html) |
| CN (4) | CN101745112A (cg-RX-API-DMAC7.html) |
| AR (2) | AR040603A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2003267999B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0312785A (cg-RX-API-DMAC7.html) |
| CA (4) | CA2880296A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1944322T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2535365T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1215265A1 (cg-RX-API-DMAC7.html) |
| IL (4) | IL166280A (cg-RX-API-DMAC7.html) |
| MX (2) | MXPA05000815A (cg-RX-API-DMAC7.html) |
| MY (2) | MY169308A (cg-RX-API-DMAC7.html) |
| NZ (5) | NZ563452A (cg-RX-API-DMAC7.html) |
| PL (3) | PL218992B1 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1944322E (cg-RX-API-DMAC7.html) |
| SI (1) | SI1944322T1 (cg-RX-API-DMAC7.html) |
| TW (3) | TWI354561B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004009776A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200500068B (cg-RX-API-DMAC7.html) |
Families Citing this family (200)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| WO1997029131A1 (en) * | 1996-02-09 | 1997-08-14 | Basf Aktiengesellschaft | HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a) |
| US7115557B2 (en) * | 1998-09-25 | 2006-10-03 | Sciaticon Ab | Use of certain drugs for treating nerve root injury |
| US20050226845A1 (en) * | 2004-03-10 | 2005-10-13 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US20060241074A1 (en) * | 2001-08-14 | 2006-10-26 | The General Hospital Corporation | Methods for treatment of pain |
| MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
| US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
| US20040136991A1 (en) * | 2002-07-19 | 2004-07-15 | Abbott Biotechnology Ltd. | Treatment of anemia using TNFalpha inhibitors |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| JP2006511620A (ja) * | 2002-12-05 | 2006-04-06 | プロテイン デザイン ラブス インコーポレイティド | 抗ｃｄ３抗体による潰瘍性大腸炎の処置方法 |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| MXPA04008070A (es) | 2003-03-10 | 2004-11-26 | Altana Pharma Ag | Novedoso proceso para la preparacion de roflumilasto. |
| CA2523267C (en) | 2003-04-23 | 2013-09-03 | Biovalve Technologies, Inc. | Hydraulically actuated pump for long duration medicament administration |
| US7553827B2 (en) * | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
| US20040229878A1 (en) * | 2003-05-13 | 2004-11-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of P38 kinase |
| US7429378B2 (en) * | 2003-05-13 | 2008-09-30 | Depuy Spine, Inc. | Transdiscal administration of high affinity anti-MMP inhibitors |
| US7344716B2 (en) * | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
| US8273347B2 (en) * | 2003-05-13 | 2012-09-25 | Depuy Spine, Inc. | Autologous treatment of degenerated disc with cells |
| US8361467B2 (en) * | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
| JP2007501243A (ja) * | 2003-08-04 | 2007-01-25 | ブリストル−マイヤーズ スクイブ カンパニー | 可溶性ｃｔｌａ４分子を用いる心臓血管疾患の治療方法 |
| US7396819B2 (en) * | 2003-08-08 | 2008-07-08 | Virbac Corporation | Anthelmintic formulations |
| JP2007510670A (ja) * | 2003-11-06 | 2007-04-26 | セルジーン・コーポレーション | サリドマイドを用いた、癌、及び他の疾患を治療、及び管理する方法ならびに組成物 |
| US8895540B2 (en) | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
| WO2005094210A2 (en) * | 2004-03-12 | 2005-10-13 | The Hartz Mountain Corporation | Multi-action anthelmintic formulations |
| TW201705980A (zh) | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
| TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| WO2006014425A1 (en) | 2004-07-02 | 2006-02-09 | Biovalve Technologies, Inc. | Methods and devices for delivering glp-1 and uses thereof |
| US20060046961A1 (en) * | 2004-09-02 | 2006-03-02 | Mckay William F | Controlled and directed local delivery of anti-inflammatory compositions |
| JP2008513479A (ja) * | 2004-09-16 | 2008-05-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アテローム性動脈硬化症および他の病理を改善するためのｇ型ペプチドおよび他の薬剤 |
| DE102004046235A1 (de) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
| US20060083741A1 (en) * | 2004-10-08 | 2006-04-20 | Hoffman Rebecca S | Treatment of respiratory syncytial virus (RSV) infection |
| RU2414236C2 (ru) * | 2004-12-06 | 2011-03-20 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье | Способ улучшения структуры и/или функций артериол |
| JP5383183B2 (ja) * | 2005-03-16 | 2014-01-08 | タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロフルミラストを含有する矯味された剤形 |
| US7431927B2 (en) | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
| AU2006230419A1 (en) * | 2005-03-31 | 2006-10-05 | Targeted Genetics Corporation | Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
| US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| AU2006242651B2 (en) * | 2005-04-29 | 2013-05-16 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| AU2012254978C1 (en) * | 2005-05-16 | 2017-06-01 | Abbvie Biotechnology Ltd | Use of TNF inhibitor for treatment of erosive polyarthritis |
| EP1885397A4 (en) * | 2005-05-16 | 2010-01-20 | Abbott Biotech Ltd | USE OF A TNF HEMMER FOR THE TREATMENT OF EROSIVE POLYARTHRITIS |
| EP1898833A2 (en) * | 2005-06-03 | 2008-03-19 | Biohesion, Inc. | Gold surfaces coated with a thermostable, chemically resistant polypeptide layer and applications thereof |
| MX2007015476A (es) | 2005-06-14 | 2008-02-25 | Amgen Inc | Formulaciones de proteina autoamortiguadoras. |
| US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| US7943134B2 (en) * | 2005-08-31 | 2011-05-17 | Academia Sinica | Compositions and methods for identifying response targets and treating flavivirus infection responses |
| US20070072247A1 (en) * | 2005-08-31 | 2007-03-29 | Academia Sinica | Methods and reagents for the analysis and purification of polysaccharides |
| DK1948235T3 (da) * | 2005-11-01 | 2013-11-25 | Abbvie Biotechnology Ltd | Fremgangsmåder til bestemmelse af effektiviteten af adalimumab hos patienter med Bechterews sygdom med CTX-II og MMP3 som biomarkører |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| PT1954718E (pt) | 2005-11-30 | 2014-12-16 | Abbvie Inc | Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos |
| US8795668B2 (en) * | 2005-12-23 | 2014-08-05 | The Regents Of The University Of Michigan | Methods for treating pulmonary fibrosis |
| US7914499B2 (en) | 2006-03-30 | 2011-03-29 | Valeritas, Inc. | Multi-cartridge fluid delivery device |
| EP2738178A1 (en) | 2006-04-05 | 2014-06-04 | AbbVie Biotechnology Ltd | Antibody purification |
| US9605064B2 (en) * | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| WO2008063213A2 (en) | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
| WO2007120626A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of ankylosing spondylitis |
| US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
| EP2012824A4 (en) * | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | USE AND COMPOSITIONS FOR THE TREATMENT OF PSORIASIS |
| US9399061B2 (en) * | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| AU2007240355B2 (en) * | 2006-04-21 | 2013-09-26 | Centocor, Inc. | CXCL13 antagonists and their use for the treatment of inflammatory diseases |
| US20100021451A1 (en) * | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
| US20080311043A1 (en) * | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| TWI527603B (zh) | 2006-06-30 | 2016-04-01 | 艾伯維生物技術有限責任公司 | 自動注射裝置 |
| NZ613356A (en) * | 2006-10-27 | 2015-02-27 | Abbvie Biotechnology Ltd | Crystalline anti-htnfalpha antibodies |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| CN101200465B (zh) * | 2006-12-11 | 2010-12-29 | 和记黄埔医药（上海）有限公司 | 一种十氢化萘类化合物及其医药用途 |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| CA2681752A1 (en) | 2007-03-29 | 2008-10-09 | Abbott Laboratories | Crystalline anti-human 1l-12 antibodies |
| US20080254011A1 (en) * | 2007-04-11 | 2008-10-16 | Peter Rothschild | Use of selected lactic acid bacteria for reducing atherosclerosis |
| WO2008141511A1 (fr) * | 2007-05-22 | 2008-11-27 | Human Antibodomics (Shanghai) Inc. | ANTICORPS MONOCLONAL HUMAIN ANTI-TNFα ET SON UTILISATION |
| US8092998B2 (en) * | 2007-05-31 | 2012-01-10 | Abbott Laboratories | Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders |
| US8999337B2 (en) * | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
| WO2009011782A2 (en) * | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR |
| US7919250B2 (en) * | 2007-07-31 | 2011-04-05 | New York University | Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions |
| WO2009020654A1 (en) * | 2007-08-08 | 2009-02-12 | Abbott Laboratories | Compositions and methods for crystallizing antibodies |
| AU2008296478B9 (en) | 2007-08-28 | 2015-03-19 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
| AU2008296487A1 (en) | 2007-08-28 | 2009-03-12 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
| WO2009052140A1 (en) * | 2007-10-15 | 2009-04-23 | Alcon Research, Ltd. | Use of tnf receptor antagonists for treating dry eye |
| US20090170770A1 (en) * | 2007-11-06 | 2009-07-02 | Ali Hafezi-Moghadam | Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor |
| TW200938221A (en) | 2007-11-30 | 2009-09-16 | Abbott Lab | Protein formulations and methods of making same |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| US20090162351A1 (en) * | 2007-12-21 | 2009-06-25 | Depuy Spine, Inc. | Transdiscal administration of inhibitors of p38 MAP kinase |
| US8986696B2 (en) * | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
| EP2238446A4 (en) * | 2008-01-03 | 2011-07-20 | Abbott Biotech Ltd | PREDICTING THE LONG-TERM EFFECT OF A CONNECTION IN THE TREATMENT OF PSORIASIS |
| NZ601913A (en) | 2008-01-15 | 2014-02-28 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
| US9365644B2 (en) * | 2008-04-23 | 2016-06-14 | Epitomics, Inc. | Anti-TNFα antibody |
| EP2350127B1 (en) * | 2008-10-20 | 2015-01-28 | AbbVie Inc. | Isolation and purification of antibodies using protein a affinity chromatography |
| CA2758964A1 (en) * | 2009-04-16 | 2010-10-21 | Abbott Biotherapeutics Corp. | Anti-tnf-.alpha. antibodies and their uses |
| BRPI1012162A2 (pt) | 2009-04-29 | 2016-01-12 | Abbott Biotech Ltd | dispositivo de injeção automática |
| CN104490767A (zh) * | 2009-05-04 | 2015-04-08 | 艾伯维生物技术有限公司 | 人抗TNF-α抗体的稳定高蛋白质浓度制剂 |
| WO2011075524A1 (en) | 2009-12-15 | 2011-06-23 | Abbott Biotechnology Ltd | Improved firing button for automatic injection device |
| WO2011084714A2 (en) * | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| CN102933601B (zh) | 2010-04-15 | 2016-06-08 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| RU2695703C2 (ru) | 2010-04-21 | 2019-07-25 | Эббви Байотекнолоджи Лтд. | Носимое устройство для автоматической инъекции для управляемой подачи терапевтических агентов |
| CN103079594B (zh) | 2010-06-03 | 2016-04-13 | 艾伯维生物技术有限公司 | 用于治疗化脓性汗腺炎(hs)的用途和组合物 |
| MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
| TWI606840B (zh) | 2010-11-11 | 2017-12-01 | 艾伯維生物技術有限責任公司 | 具有增進高濃度之抗-ＴＮＦα抗體之液體調配物 |
| CA2825316C (en) | 2011-01-24 | 2020-05-05 | Abbvie Biotechnology Ltd. | Automatic injection devices having overmolded gripping surfaces |
| JP2014511393A (ja) * | 2011-03-07 | 2014-05-15 | セルジーン コーポレイション | イソインドリン化合物を用いた疾患の治療方法 |
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| US9642888B2 (en) * | 2011-04-12 | 2017-05-09 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| AU2012311908A1 (en) * | 2011-09-23 | 2014-03-27 | Westfalische Wilhelms-Universitaet Muenster | Yersinia outer protein m (YopM) in the treatment of psoriasis |
| US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
| US9580490B2 (en) | 2012-06-21 | 2017-02-28 | Hanall Biopharma Co., Ltd. | Uses of modified human tumor necrosis factor receptor-1 polypeptide |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| WO2014035475A1 (en) | 2012-09-02 | 2014-03-06 | Abbvie Inc. | Methods to control protein heterogeneity |
| CN110193077A (zh) * | 2012-10-22 | 2019-09-03 | 康德生物医疗技术公司 | 降低与心脏衰竭相关的风险和与其相关的因素的方法 |
| US20140255403A1 (en) * | 2013-03-06 | 2014-09-11 | Hadasit Medical Research Services & Development Ltd. | Oral composition comprising a tnf antagonist and use thereof |
| CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| HK1219533A1 (zh) | 2013-03-15 | 2017-04-07 | Intermune, Inc. | 蛋白质组学ipf标志物 |
| TWI516272B (zh) * | 2013-06-05 | 2016-01-11 | 財團法人工業技術研究院 | 應用於生髮之方法及醫藥組成物 |
| CN104341502B (zh) * | 2013-08-09 | 2016-04-27 | 北京天成新脉生物技术有限公司 | 低免疫原性抗TNF-α全人源单抗及其应用 |
| PL226431B1 (pl) | 2013-08-23 | 2017-07-31 | Inst Biochemii I Biofizyki Polskiej Akademii Nauk | Cząsteczka miRNA do zastosowania do wytwarzania leku do zmniejszania reakcji zapalnej lub zapobiegania zwiększaniu się reakcji zapalnej organizmu |
| EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| MX374124B (es) | 2013-10-16 | 2025-03-05 | Outlook Therapeutics Inc | Formulaciones de tampón para la estabilidad de anticuerpo mejorada. |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| CN103961694A (zh) * | 2014-04-18 | 2014-08-06 | 陶惠人 | 基于p-硝基苯丙氨酸插入法构建的骨质疏松疫苗 |
| WO2015200260A1 (en) * | 2014-06-24 | 2015-12-30 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
| US10351621B2 (en) | 2014-06-24 | 2019-07-16 | Immunomedics, Inc. | Anti-histone therapy in acute kidney injury |
| US9775978B2 (en) | 2014-07-25 | 2017-10-03 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
| US9764122B2 (en) | 2014-07-25 | 2017-09-19 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having an occluding member |
| EP3189069B1 (en) | 2014-07-31 | 2024-10-23 | UAB Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
| CA2966573A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
| KR102709593B1 (ko) * | 2014-11-05 | 2024-09-26 | 제넨테크, 인크. | 박테리아 내 2쇄 단백질을 생산하는 방법 |
| HK1243940A1 (zh) | 2014-11-06 | 2018-07-27 | Scholar Rock, Inc. | 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途 |
| EP3227880B1 (en) * | 2014-12-01 | 2018-09-26 | Truinject Corp. | Injection training tool emitting omnidirectional light |
| EP3247718B1 (en) | 2015-01-21 | 2021-09-01 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| US10465224B2 (en) | 2015-02-03 | 2019-11-05 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing and treating arthritis |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| CN107427577A (zh) | 2015-03-31 | 2017-12-01 | 韦斯夸尔德有限公司 | 具有蛋白酶可切割接头的肽构建体 |
| ES2973042T3 (es) | 2015-03-31 | 2024-06-18 | Sorriso Pharmaceuticals Inc | Polipéptidos |
| EP3078675A1 (en) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induction dosing regimen for the treatment of tnf alpha mediated disorders |
| US10519207B2 (en) | 2015-06-12 | 2019-12-31 | Georgia State University Research Foundation, Inc. | Compositions and methods for treating opioid tolerance |
| CN105175529A (zh) * | 2015-07-16 | 2015-12-23 | 中国科学院海洋研究所 | 一种鱼类肿瘤坏死因子家族蛋白的重组蛋白及其应用 |
| CA3031430A1 (en) * | 2015-07-22 | 2017-01-26 | Scholar Rock, Inc. | Gdf11 binding proteins and uses thereof |
| CN113896789A (zh) | 2015-09-15 | 2022-01-07 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途 |
| US10076650B2 (en) | 2015-11-23 | 2018-09-18 | Warsaw Orthopedic, Inc. | Enhanced stylet for drug depot injector |
| CN109071645A (zh) | 2016-01-08 | 2018-12-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| WO2017136433A1 (en) | 2016-02-03 | 2017-08-10 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
| US10465003B2 (en) * | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
| IL301468A (en) | 2016-06-13 | 2023-05-01 | Scholar Rock Inc | Use of myostatin inhibitors and combination therapies |
| USD802755S1 (en) | 2016-06-23 | 2017-11-14 | Warsaw Orthopedic, Inc. | Drug pellet cartridge |
| WO2018045213A1 (en) * | 2016-09-02 | 2018-03-08 | 180 Therapeutics Lp | Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody |
| WO2018045258A1 (en) * | 2016-09-02 | 2018-03-08 | The University Of Chicago | TREATMENT OF TNF-alpha CYTOTOXICITY |
| EP3519438A1 (en) | 2016-09-30 | 2019-08-07 | VHsquared Limited | Compositions |
| CA3040899A1 (en) | 2016-10-21 | 2018-04-26 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
| US10434261B2 (en) | 2016-11-08 | 2019-10-08 | Warsaw Orthopedic, Inc. | Drug pellet delivery system and method |
| CN118873822A (zh) * | 2016-12-14 | 2024-11-01 | 比奥拉治疗股份有限公司 | 使用tnf抑制剂治疗胃肠道疾病 |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| HRP20230308T1 (hr) | 2017-01-06 | 2023-05-12 | Scholar Rock, Inc. | Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina |
| WO2018195764A1 (zh) * | 2017-04-25 | 2018-11-01 | 群康生技股份有限公司 | 注射笔 |
| KR101946884B1 (ko) * | 2017-04-25 | 2019-02-13 | 고려대학교 산학협력단 | 대사체 분석을 이용한 베체트병의 진단방법 |
| CA3066361A1 (en) | 2017-06-07 | 2018-12-13 | Shifamed Holdings, Llc | Intravascular fluid movement devices, systems, and methods of use |
| KR20190024572A (ko) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | TNFα 관련 질환을 치료하기 위한 피하 투여 요법 |
| CN107362351B (zh) * | 2017-09-04 | 2020-11-10 | 上海市儿童医院 | Il-36r的拮抗剂在制备镇痛药物中的应用 |
| EP3710076B1 (en) | 2017-11-13 | 2023-12-27 | Shifamed Holdings, LLC | Intravascular fluid movement devices, systems, and methods of use |
| CN112004563B (zh) | 2018-02-01 | 2024-08-06 | 施菲姆德控股有限责任公司 | 血管内血泵以及使用和制造方法 |
| CN108588040B (zh) * | 2018-06-08 | 2021-06-15 | 中国医学科学院病原生物学研究所 | 重组MtMetRS、其晶体及它们在制备抗结核药物中的应用 |
| JP2021530553A (ja) * | 2018-07-25 | 2021-11-11 | ラッシュ ユニバーシティ メディカル センターRush University Medical Center | 標的サイトカイン枯渇による腎臓病の再発の抑制 |
| US12161857B2 (en) | 2018-07-31 | 2024-12-10 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use |
| WO2020073047A1 (en) | 2018-10-05 | 2020-04-09 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use |
| US12232867B2 (en) * | 2018-10-26 | 2025-02-25 | Abbott Diabetes Care Inc. | Methods, devices, and systems for physiological parameter analysis |
| EP3897853A1 (en) | 2018-12-20 | 2021-10-27 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains |
| CN109998488B (zh) * | 2019-04-13 | 2022-08-02 | 中国医学科学院北京协和医院 | 克罗恩病和肠道溃疡型淋巴瘤的鉴别模型及构建方法 |
| EP3969456A4 (en) * | 2019-05-17 | 2023-01-25 | Celgene CAR LLC | METHODS OF TREATMENT OF MK2-MEDIATED DISEASE |
| BR112021025416A2 (pt) * | 2019-06-17 | 2022-02-22 | Mayo Found Medical Education & Res | Preparações de prevotella e tratamento de doença pulmonar obstrutiva crônica (dpoc) e outras condições pulmonares |
| AU2020296979A1 (en) | 2019-06-21 | 2022-02-24 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| CN114466864B (zh) | 2019-06-21 | 2024-12-27 | 索瑞索制药公司 | 多肽 |
| JP2022540616A (ja) | 2019-07-12 | 2022-09-16 | シファメド・ホールディングス・エルエルシー | 血管内血液ポンプならびに製造および使用の方法 |
| WO2021016372A1 (en) | 2019-07-22 | 2021-01-28 | Shifamed Holdings, Llc | Intravascular blood pumps with struts and methods of use and manufacture |
| US12465748B2 (en) | 2019-08-07 | 2025-11-11 | Supira Medical, Inc. | Catheter blood pumps and collapsible pump housings |
| CA3149049A1 (en) * | 2019-08-30 | 2021-03-04 | Vestlandets Innovasjonsselskap As | Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells |
| WO2021062260A1 (en) | 2019-09-25 | 2021-04-01 | Shifamed Holdings, Llc | Catheter blood pumps and collapsible blood conduits |
| EP4034192B1 (en) | 2019-09-25 | 2025-12-24 | Supira Medical, Inc. | Intravascular blood pump systems and methods of use and control thereof |
| EP4501393A3 (en) | 2019-09-25 | 2025-04-09 | Shifamed Holdings, LLC | Catheter blood pumps and collapsible pump housings |
| US20230025003A1 (en) * | 2019-10-18 | 2023-01-26 | BioZipcode, Inc. | Diabetes therapy targeting abnormal stem cells |
| EP4072650A4 (en) | 2019-12-11 | 2024-01-10 | Shifamed Holdings, LLC | Descending aorta and vena cava blood pumps |
| TWI807338B (zh) * | 2020-06-26 | 2023-07-01 | 美商美國禮來大藥廠 | 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途 |
| WO2022120421A1 (en) * | 2020-12-09 | 2022-06-16 | Servatus Ltd | Combination therapy for inflammatory disorders of the joints |
| AU2023413166A1 (en) | 2022-12-22 | 2025-07-03 | Scholar Rock, Inc. | Selective and potent inhibitory antibodies of myostatin activation |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6448A (en) | 1849-05-15 | Improvement in cut-offs and steam-stops of rotary engines | ||
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5959087A (en) * | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
| US6498237B2 (en) * | 1989-08-07 | 2002-12-24 | Peptech Limited | Tumor necrosis factor antibodies |
| FR2651130B1 (fr) * | 1989-08-23 | 1991-12-13 | Roussel Uclaf | Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques. |
| CA2065346C (en) | 1989-09-05 | 2005-03-29 | Craig A. Smith | Tumor necrosis factor-.alpha. and-.beta. receptors |
| US20020099179A1 (en) * | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5994510A (en) * | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
| AU1545692A (en) | 1991-03-01 | 1992-10-06 | Protein Engineering Corporation | Process for the development of binding mini-proteins |
| US20060246073A1 (en) * | 1991-03-18 | 2006-11-02 | Knight David M | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US20070298040A1 (en) * | 1991-03-18 | 2007-12-27 | Centocor, Inc. | Methods of treating seronegative arthropathy with anti-TNF antibodies |
| US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| US20040120952A1 (en) * | 2000-08-07 | 2004-06-24 | Centocor, Inc | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| EP1097945B1 (en) * | 1991-03-18 | 2007-07-04 | New York University | Monoclonal and chimeric antibody specific for human tumor necrosis factor |
| US5658727A (en) | 1991-04-10 | 1997-08-19 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| AU3924993A (en) | 1992-04-02 | 1993-11-08 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
| NZ256293A (en) | 1992-09-15 | 1997-06-24 | Immunex Corp | Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist |
| US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
| EP0614984B2 (en) * | 1993-03-05 | 2010-11-03 | Bayer HealthCare LLC | Anti-TNF alpha human monoclonal antibodies |
| NZ278607A (en) * | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| WO1997029313A1 (en) * | 1996-02-08 | 1997-08-14 | Warwick Andrew Mckenzie | Lockable coupling |
| WO1997029131A1 (en) * | 1996-02-09 | 1997-08-14 | Basf Aktiengesellschaft | HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a) |
| EP0816357B1 (en) * | 1996-06-27 | 2002-01-09 | Pfizer Inc. | Substituted indazole derivatives |
| KR20000053274A (ko) * | 1996-11-15 | 2000-08-25 | 마르크 젠너 | 이환식 아릴 카르복사미드 및 그의 치료학적 용도 |
| WO1998051344A1 (en) * | 1997-05-12 | 1998-11-19 | The Kennedy Institute Of Rheumatology | Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy |
| JPH11127882A (ja) * | 1997-10-27 | 1999-05-18 | Nippon Kayaku Co Ltd | 新規生理活性物質ｎｋ３０４２４ａ，ｎｋ３０４２４ｂ，それらの製造法およびそれらの用途 |
| US6379666B1 (en) * | 1999-02-24 | 2002-04-30 | Edward L. Tobinick | TNF inhibitors for the treatment of neurological, retinal and muscular disorders |
| US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
| US6423321B2 (en) * | 1999-02-24 | 2002-07-23 | Edward L. Tobinick | Cytokine antagonists for the treatment of sensorineural hearing loss |
| US6537549B2 (en) * | 1999-02-24 | 2003-03-25 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| US6419944B2 (en) * | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| EP1041072B1 (en) * | 1999-03-31 | 2003-07-16 | Pfizer Products Inc. | Dioxocyclopentyl hydroxamic acids |
| US20010021380A1 (en) * | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US6833268B1 (en) * | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| AU3082401A (en) * | 1999-11-24 | 2001-06-04 | Centocor Inc. | Therapy of psoriasis |
| JP4812921B2 (ja) * | 2000-04-14 | 2011-11-09 | 田辺三菱製薬株式会社 | ベーチェット病治療剤 |
| GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| US20060018907A1 (en) * | 2000-08-07 | 2006-01-26 | Centocor, Inc. | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| UA81743C2 (uk) * | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| US20050249735A1 (en) * | 2000-08-07 | 2005-11-10 | Centocor, Inc. | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
| EP2325205A3 (en) * | 2000-12-28 | 2011-10-12 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| BR0206160A (pt) * | 2001-05-25 | 2004-10-26 | Abbott Gmbh & Co Kg | Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos |
| CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US20030161828A1 (en) * | 2002-02-19 | 2003-08-28 | Abbott Gmbh & Co. Kg | Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure |
| US20030206898A1 (en) * | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
| US20040136991A1 (en) * | 2002-07-19 | 2004-07-15 | Abbott Biotechnology Ltd. | Treatment of anemia using TNFalpha inhibitors |
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| WO2004045512A2 (en) * | 2002-11-15 | 2004-06-03 | Genmab A/S | Human monoclonal antibodies against cd25 |
| US7101978B2 (en) * | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
| US20040193466A1 (en) * | 2003-03-27 | 2004-09-30 | Irena Kull | Method and process for managing a yard |
| TW201705980A (zh) * | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| US20060083741A1 (en) * | 2004-10-08 | 2006-04-20 | Hoffman Rebecca S | Treatment of respiratory syncytial virus (RSV) infection |
| EP1885397A4 (en) * | 2005-05-16 | 2010-01-20 | Abbott Biotech Ltd | USE OF A TNF HEMMER FOR THE TREATMENT OF EROSIVE POLYARTHRITIS |
| US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| DK1948235T3 (da) * | 2005-11-01 | 2013-11-25 | Abbvie Biotechnology Ltd | Fremgangsmåder til bestemmelse af effektiviteten af adalimumab hos patienter med Bechterews sygdom med CTX-II og MMP3 som biomarkører |
| EP2738178A1 (en) * | 2006-04-05 | 2014-06-04 | AbbVie Biotechnology Ltd | Antibody purification |
| US9399061B2 (en) * | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
| WO2007120626A2 (en) * | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of ankylosing spondylitis |
| WO2008063213A2 (en) * | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
| US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| US20100021451A1 (en) * | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
| US20080311043A1 (en) * | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| TWI527603B (zh) * | 2006-06-30 | 2016-04-01 | 艾伯維生物技術有限責任公司 | 自動注射裝置 |
| KR20090074040A (ko) * | 2006-09-13 | 2009-07-03 | 아보트 러보러터리즈 | 세포 배양의 개선 |
| NZ613356A (en) * | 2006-10-27 | 2015-02-27 | Abbvie Biotechnology Ltd | Crystalline anti-htnfalpha antibodies |
| US8092998B2 (en) * | 2007-05-31 | 2012-01-10 | Abbott Laboratories | Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders |
| EP2152318A4 (en) * | 2007-06-01 | 2011-12-07 | Abbott Biotech Ltd | COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE |
| US8999337B2 (en) * | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
| WO2009011782A2 (en) * | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR |
| WO2009020654A1 (en) * | 2007-08-08 | 2009-02-12 | Abbott Laboratories | Compositions and methods for crystallizing antibodies |
| TW200938221A (en) * | 2007-11-30 | 2009-09-16 | Abbott Lab | Protein formulations and methods of making same |
| EP2238446A4 (en) * | 2008-01-03 | 2011-07-20 | Abbott Biotech Ltd | PREDICTING THE LONG-TERM EFFECT OF A CONNECTION IN THE TREATMENT OF PSORIASIS |
| KR20100113112A (ko) * | 2008-01-15 | 2010-10-20 | 아보트 러보러터리즈 | 개선된 포유동물 발현 벡터 및 이의 용도 |
| NZ601913A (en) * | 2008-01-15 | 2014-02-28 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
| CN102282173A (zh) * | 2008-03-24 | 2011-12-14 | 艾博特生物技术有限公司 | 用于治疗骨丢失的方法和组合物 |
| WO2010083042A1 (en) * | 2009-01-15 | 2010-07-22 | Manta Devices, Llc | Delivery device |
| BRPI1012162A2 (pt) * | 2009-04-29 | 2016-01-12 | Abbott Biotech Ltd | dispositivo de injeção automática |
| CN104490767A (zh) * | 2009-05-04 | 2015-04-08 | 艾伯维生物技术有限公司 | 人抗TNF-α抗体的稳定高蛋白质浓度制剂 |
-
2003
- 2003-07-18 US US10/623,075 patent/US20040136991A1/en not_active Abandoned
- 2003-07-18 MY MYPI2013004323A patent/MY169308A/en unknown
- 2003-07-18 KR KR1020147007746A patent/KR20140058649A/ko not_active Ceased
- 2003-07-18 US US10/623,318 patent/US20130243786A1/en not_active Abandoned
- 2003-07-18 CA CA2880296A patent/CA2880296A1/en not_active Abandoned
- 2003-07-18 TW TW092119891A patent/TWI354561B/zh not_active IP Right Cessation
- 2003-07-18 PL PL401886A patent/PL218992B1/pl unknown
- 2003-07-18 JP JP2005505532A patent/JP2006506465A/ja not_active Withdrawn
- 2003-07-18 CA CA2800126A patent/CA2800126A1/en not_active Abandoned
- 2003-07-18 CN CN200910253363A patent/CN101745112A/zh active Pending
- 2003-07-18 US US10/622,932 patent/US20040126372A1/en not_active Abandoned
- 2003-07-18 TW TW098127343A patent/TWI430810B/zh not_active IP Right Cessation
- 2003-07-18 PL PL374865A patent/PL213925B1/pl unknown
- 2003-07-18 US US10/623,076 patent/US20040131614A1/en not_active Abandoned
- 2003-07-18 MY MYPI20032713 patent/MY151032A/en unknown
- 2003-07-18 AU AU2003267999A patent/AU2003267999B2/en not_active Expired
- 2003-07-18 EP EP07150442.7A patent/EP1944322B1/en not_active Revoked
- 2003-07-18 KR KR1020127030281A patent/KR20130001318A/ko not_active Ceased
- 2003-07-18 US US10/622,928 patent/US20040151722A1/en not_active Abandoned
- 2003-07-18 AR AR20030102605A patent/AR040603A1/es not_active Application Discontinuation
- 2003-07-18 KR KR1020127001635A patent/KR101283877B1/ko not_active Ceased
- 2003-07-18 ES ES07150442.7T patent/ES2535365T3/es not_active Expired - Lifetime
- 2003-07-18 EP EP15157149.4A patent/EP2942359A1/en not_active Withdrawn
- 2003-07-18 BR BR0312785-0A patent/BR0312785A/pt not_active Application Discontinuation
- 2003-07-18 DK DK07150442.7T patent/DK1944322T3/da active
- 2003-07-18 CA CA2803741A patent/CA2803741A1/en not_active Withdrawn
- 2003-07-18 PT PT71504427T patent/PT1944322E/pt unknown
- 2003-07-18 WO PCT/US2003/022566 patent/WO2004009776A2/en not_active Ceased
- 2003-07-18 CN CNA038224550A patent/CN1691963A/zh active Pending
- 2003-07-18 US US10/623,039 patent/US20070202104A1/en not_active Abandoned
- 2003-07-18 KR KR1020057001064A patent/KR20050042466A/ko not_active Ceased
- 2003-07-18 US US10/623,035 patent/US20040136990A1/en not_active Abandoned
- 2003-07-18 US US10/622,205 patent/US20040219142A1/en not_active Abandoned
- 2003-07-18 KR KR1020117004851A patent/KR20110027851A/ko not_active Ceased
- 2003-07-18 EP EP10182274A patent/EP2336182A1/en not_active Ceased
- 2003-07-18 US US10/622,210 patent/US20040136989A1/en not_active Abandoned
- 2003-07-18 EP EP03748949A patent/EP1542720A4/en not_active Withdrawn
- 2003-07-18 US US10/623,065 patent/US20040126373A1/en not_active Abandoned
- 2003-07-18 CN CN2012102392380A patent/CN102755646A/zh active Pending
- 2003-07-18 SI SI200332414T patent/SI1944322T1/sl unknown
- 2003-07-18 TW TW101135423A patent/TWI527592B/zh not_active IP Right Cessation
- 2003-07-18 CA CA002493067A patent/CA2493067A1/en not_active Abandoned
- 2003-07-18 NZ NZ563452A patent/NZ563452A/en not_active IP Right Cessation
- 2003-07-18 EP EP10183702A patent/EP2298810A3/en not_active Withdrawn
- 2003-07-18 EP EP10182730A patent/EP2371859A3/en not_active Withdrawn
- 2003-07-18 MX MXPA05000815A patent/MXPA05000815A/es active IP Right Grant
- 2003-07-18 NZ NZ598346A patent/NZ598346A/xx not_active IP Right Cessation
- 2003-07-18 NZ NZ555692A patent/NZ555692A/en not_active IP Right Cessation
- 2003-07-18 CN CN2012102392802A patent/CN102764436A/zh active Pending
- 2003-07-18 PL PL397846A patent/PL217223B1/pl unknown
- 2003-07-18 NZ NZ587754A patent/NZ587754A/en not_active IP Right Cessation
- 2003-07-18 MX MX2009003691A patent/MX342777B/es unknown
- 2003-07-18 KR KR20157009634A patent/KR20150043568A/ko not_active Withdrawn
-
2005
- 2005-01-04 ZA ZA2005/00068A patent/ZA200500068B/en unknown
- 2005-01-13 IL IL166280A patent/IL166280A/en active IP Right Grant
-
2008
- 2008-04-14 US US12/102,682 patent/US20080193466A1/en not_active Abandoned
-
2009
- 2009-05-06 NZ NZ576774A patent/NZ576774A/en not_active IP Right Cessation
-
2010
- 2010-02-25 AU AU2010200708A patent/AU2010200708B2/en not_active Expired
- 2010-03-15 JP JP2010057713A patent/JP2010209070A/ja active Pending
- 2010-07-14 AR ARP100102563A patent/AR077474A2/es not_active Application Discontinuation
- 2010-12-19 IL IL210091A patent/IL210091A/en active IP Right Grant
- 2010-12-19 IL IL210090A patent/IL210090A0/en unknown
-
2011
- 2011-06-06 IL IL213400A patent/IL213400A0/en unknown
-
2012
- 2012-10-11 JP JP2012225755A patent/JP2013056892A/ja not_active Withdrawn
-
2013
- 2013-05-28 US US13/903,525 patent/US20130243763A1/en not_active Abandoned
-
2014
- 2014-05-02 US US14/268,628 patent/US20140286941A1/en not_active Abandoned
- 2014-05-02 US US14/268,449 patent/US20140286939A1/en not_active Abandoned
- 2014-05-02 US US14/268,614 patent/US20140286940A1/en not_active Abandoned
-
2015
- 2015-06-09 JP JP2015116695A patent/JP2015221798A/ja active Pending
- 2015-09-03 US US14/844,578 patent/US20150368335A1/en not_active Abandoned
-
2016
- 2016-03-18 HK HK16103196.8A patent/HK1215265A1/en unknown